Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test

News   Jun 16, 2016

 
Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test
 
 
 

RELATED ARTICLES

The Protein Lasso Implicated in Breast Cancer

News

Certain types of RNA are implicated in the production of pro-breast cancer proteins. Now, a new study has shed light on the mechanism by which these RNAs manipulate DNA to produce these proteins.

READ MORE

Smart Phone Developed for Quicker Infection Testing

News

Washington State University researchers have developed a low-cost, portable laboratory on a phone that works nearly as well as clinical laboratories to detect common viral and bacterial infections.

READ MORE

Sweet Spot of Activity in Immune System Key to Fighting Cancer

News

Scientists have shown how stimulating a specific location on the surface of immune cells can be targeted with antibodies to help in their fight against cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Diagnostics Proteomics & Metabolomics Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE